JP2009525478A5 - - Google Patents

Download PDF

Info

Publication number
JP2009525478A5
JP2009525478A5 JP2008552858A JP2008552858A JP2009525478A5 JP 2009525478 A5 JP2009525478 A5 JP 2009525478A5 JP 2008552858 A JP2008552858 A JP 2008552858A JP 2008552858 A JP2008552858 A JP 2008552858A JP 2009525478 A5 JP2009525478 A5 JP 2009525478A5
Authority
JP
Japan
Prior art keywords
cancer
prongf
body fluid
biological sample
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008552858A
Other languages
English (en)
Japanese (ja)
Other versions
JP5091876B2 (ja
JP2009525478A (ja
Filing date
Publication date
Priority claimed from FR0600851A external-priority patent/FR2896881B1/fr
Application filed filed Critical
Publication of JP2009525478A publication Critical patent/JP2009525478A/ja
Publication of JP2009525478A5 publication Critical patent/JP2009525478A5/ja
Application granted granted Critical
Publication of JP5091876B2 publication Critical patent/JP5091876B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008552858A 2006-01-31 2007-01-30 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのProNGFアッセイのための方法とProNGFの治療的使用 Expired - Fee Related JP5091876B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0600851 2006-01-31
FR0600851A FR2896881B1 (fr) 2006-01-31 2006-01-31 Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
PCT/FR2007/050708 WO2007088305A1 (fr) 2006-01-31 2007-01-30 Procede de dosage du prongf pour le diagnostic in vitro du cancer en particulier du cancer du sein, de la thyroide ou du poumon et utilisation du prongf en therapie

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012124525A Division JP5792121B2 (ja) 2006-01-31 2012-05-31 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのProNGFアッセイのための方法とProNGFの治療的使用

Publications (3)

Publication Number Publication Date
JP2009525478A JP2009525478A (ja) 2009-07-09
JP2009525478A5 true JP2009525478A5 (cg-RX-API-DMAC7.html) 2010-03-04
JP5091876B2 JP5091876B2 (ja) 2012-12-05

Family

ID=36741378

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008552858A Expired - Fee Related JP5091876B2 (ja) 2006-01-31 2007-01-30 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのProNGFアッセイのための方法とProNGFの治療的使用
JP2012124525A Expired - Fee Related JP5792121B2 (ja) 2006-01-31 2012-05-31 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのProNGFアッセイのための方法とProNGFの治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012124525A Expired - Fee Related JP5792121B2 (ja) 2006-01-31 2012-05-31 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのProNGFアッセイのための方法とProNGFの治療的使用

Country Status (7)

Country Link
US (3) US8008009B2 (cg-RX-API-DMAC7.html)
EP (1) EP1982192B1 (cg-RX-API-DMAC7.html)
JP (2) JP5091876B2 (cg-RX-API-DMAC7.html)
CN (2) CN103446585A (cg-RX-API-DMAC7.html)
ES (1) ES2471126T3 (cg-RX-API-DMAC7.html)
FR (1) FR2896881B1 (cg-RX-API-DMAC7.html)
WO (1) WO2007088305A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896881B1 (fr) * 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
FR2944019B1 (fr) * 2009-04-03 2011-04-22 Biomerieux Sa Procede de dosage de la prodefensine-a6 pour le diagnostic in vitro du cancer colorectal.
EP3360978A3 (en) 2009-05-07 2018-09-26 Veracyte, Inc. Methods for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
CN101782585A (zh) * 2010-02-10 2010-07-21 广州医学院 肺癌组织蛋白印迹膜片及其制备方法
WO2011159762A1 (en) * 2010-06-15 2011-12-22 Cornell University Methods of limiting microvascular damage following acute myocardial ischemia
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
WO2013016600A2 (en) * 2011-07-28 2013-01-31 The Trustees Of The University Of Pennsylvania Methods and reagents for diagnosing conditions and characterization of tumor cells associated with serous fluids
EP2791359B1 (en) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
CN103122390B (zh) * 2013-03-07 2015-04-08 上海市疾病预防控制中心 Frat1基因作为检测甲状腺癌的血清标志物及其应用
EP2968988A4 (en) 2013-03-14 2016-11-16 Allegro Diagnostics Corp METHOD FOR EVALUATING A COPD STATUS
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
CN103866039B (zh) * 2014-04-04 2015-05-27 厦门大学 人类甲状腺癌组织基因特异位点甲基化水平检测引物及其应用
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US10365272B2 (en) * 2014-07-25 2019-07-30 Serum Institute Of India Private Limited Highly sensitive immunoassay for rapid quantification of meningococcal capsular polysaccharide antigens
CN114606309A (zh) 2014-11-05 2022-06-10 威拉赛特公司 使用机器学习和高维转录数据的诊断系统和方法
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
EP3991748A3 (en) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
US20200102617A1 (en) * 2017-01-24 2020-04-02 Genetic Technologies Limited Improved Methods For Assessing Risk of Developing Breast Cancer
AU2018230784A1 (en) 2017-03-09 2019-10-10 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018205035A1 (en) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
CA3066507A1 (fr) * 2017-06-08 2018-12-13 Carcidiag Biotechnologies Methode d'isolement et de detection de cellules souches cancereuses
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
SMT202300110T1 (it) 2018-07-13 2023-05-12 Alector Llc Anticorpi anti-sortilina e relativi metodi di uso

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
ATE331958T1 (de) 2002-03-13 2006-07-15 Biomerieux Sa Verfahren zum nachweis und zur quantifizierung von -aus soliden tumoren abstammenden- zirkulierenden tumorzellen
FR2846426B1 (fr) * 2002-10-28 2004-12-10 Bio Merieux Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
DK1891966T3 (da) * 2002-12-20 2012-04-02 Lundbeck & Co As H Modulation af neurotrophinaktivitet; fremgangsmåde til screening
EP1718308A4 (en) * 2004-02-11 2007-07-18 Painceptor Pharma Corp PROCESS FOR MODULATING NEUROTROPHINE-MEDIATED ACTIVITY
FR2896881B1 (fr) * 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie

Similar Documents

Publication Publication Date Title
Wilmott et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma
Houshmand et al. Chronic myeloid leukemia stem cells
Mercer et al. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
Kelly et al. The dynamic and transient immune microenvironment in locally advanced esophageal adenocarcinoma post chemoradiation
Jimeno et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development
US9670550B2 (en) Method for examination of carcinogenic risk
Lerévérend et al. Enhanced expression of galectin‐9 in triple negative breast cancer cells following radiotherapy: Implications for targeted therapy
Wang et al. The prediction of survival of patients with gastric cancer with PD-L1 expression using contrast-enhanced ultrasonography
Dudek et al. Antineoplastic effects of Rhodiola crenulata treatment on B16-F10 melanoma
Tarhini et al. Operable melanoma: screening, prognostication, and adjuvant and neoadjuvant therapy
US20090226901A1 (en) Method of evaluating or selecting agents for preventing or improving pigmented spots
Dai et al. Tumor vascular normalization by B7-H3 blockade augments T lymphocyte-mediated antitumor immunity
US11988672B2 (en) CCL24 as a diagnostic and therapeutic target for breast cancer
CN112262157A (zh) 化药抗性癌症的组合治疗
FR2840905B1 (fr) Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
Ollila-Raj et al. Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing
RU2436102C1 (ru) Способ прогнозирования метастазов рака шейки матки
Duarte et al. 173eP Detection of HER2 amplification in Circulating Cell-Free DNA by digital PCR in HER2 0 metastatic breast cancer
Akhvlediani et al. 176eP Neuroendocrine disruption in triple-negative Breast Cancer: Dopamine deficiency as a prognostic marker and potential therapeutic target
CN119700754A (zh) Ido1抑制剂在制备治疗儿童脓毒症相关性胸腺萎缩的药物中的应用
Rida et al. 174eP Predictive and prognostic role of p53 in achieving pCR in breast cancer patients after neoadjuvant chemotherapy
He et al. The Expression of PD-L1, CD47, CD4, and CD8 in Breast Cancer before and after Neoadjuvant Chemotherapy and Their Relationship with Clinicopathological Features and Prognosis
Lee et al. A NON-GENETICALLY ENGINEERED EGFR SPECIFIC ARMED T-CELL THERAPY FOR TREATING EGFR-POSITIVE SOLID TUMORS
Alessandro et al. 225 ALK. CAR-T cells as a new potential treatment for ALK+ merkel cell carcinoma
Yamashita et al. GENE-31. DETECTION OF MGMT PROMOTER METHYLATION LEVELS WITH MS-HRM IN PATIENTS WITH GLIOBLASTOMA